Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy emphasizing “scale-out” manufacturing, to derisk demand uncertainty, speed timelines and conserve cash for emerging drug developers.

Original title: “Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies”

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn Pharma filed a registration statement on Wednesday seeking to raise capital to develop its pipeline of respiratory disease treatments. GEN – Genetic Engineering and Biotechnology News ... Novavax rises on second largest shareholder's opposition to board nominee choices, executive pay packages ... The exterior of the New York Stock Exchange. The initial public offering (IPO) market showed its first signs of life in more than a month as Boston-based Avalyn Pharma filed a registration statement on Wednesday seeking to raise capital toward developing its pipeline of respiratory disease treatments. AP03 would be advanced into the clinic and Phase I topline data using capital from the IPO. Whatever isn’t spent on the pipeline candidates will be set aside for R&D activities for additional programs, working capital, and general corporate purposes, Avalyn added. Avalyn is the first biotech IPO filing since Generate: Biomedicines completed the year’s largest to date, raising $400 million in gross proceeds toward clinical trials, as well as platform and pipeline R&D efforts. To date, seven companies have completed biotech IPOs, raising just over $1.7 billion in combined proceeds, Jefferies analyst Andrew Tsai wrote in a research note. “Management has failed to implement aggressive cost-cutting measures necessary to achieve consistent profitability,” Himanshu H. Shah, the fund’s managing partner and chief investment officer, advocated in an open letter to Novavax’s board. “The current senior management team should be reduced by 30% to reflect Novavax’s new royalty and partnership business model.”

Original title: “StockWatch: IPO Market Shows Sign of Life with Avalyn Filing”

Juno, a San Diego-based tax preparation automation platform, secured $12 million in Seed funding, le || Read More on Medial

Original title: “Juno Raises $12 Million in Seed Funding | The SaaS News | Medial”

India is a global pharmacy powerhouse, but not yet a deep science leader. The gap between talent and trust may be pushing innovation away. An X post claims India’s best biotech startups are moving abroad. A recent X post by Dilip Kumar, an investor in founders at Rainmatterin and Zerodhaonline, has raised a serious conversation about India’s biotech ecosystem. The post describes a founder, trained at Yale, who returned to India to build a biotech company working on vaccines for deadly cancers, only to struggle with raising funds and navigating regulations. The founder mentioned in the X post reportedly struggled to raise venture capital because most investors are unwilling to commit to 7–10 year timelines, which are typical for biotech innovation.

Original title: “India’s biotech startup problem: X post points to funding, policy gaps - India Today”

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.

Original title: “Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors”

The newly published charter widens the required expertise to become an ACIP member and stresses vaccine safety. Elsewhere, Gilead licensed a Kymera drug and a new RNA-focused startup emerged.

Original title: “RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders”

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has come from behind the Danish rival in the weight loss space before, last time it clearly had the better drug.

Original title: “With oral obesity race underway, all eyes are on Lilly’s Foundayo launch”

In the future of AI-driven biopharma, reusable data is the most undervalued asset.

Original title: “Opinion: For AI to have impact, the industry must align on data”

Persistent barriers are still hindering drug development for a host of menopause symptoms.

Original title: “Women have awaited a revolution in menopause. It hasn’t arrived.”

Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and ... Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulat... Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.

Original title: “COAG IPO News - Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO”

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idiopathic pulmonary fibrosis.

Original title: “Chasing a tough-to-treat lung disease, Avalyn plans an IPO”

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

Original title: “Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk”

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

Original title: “Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic”

Partnership to develop next‑generation T‑cell engagers for solid tumours

Original title: “Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb”

The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial clients as it works to expand the plant’s capacity to 172,000 liters.

Original title: “Innovent’s CDMO gets green light to make biologics at large Chinese plant”

Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.

Original title: “Roche sticks with C4T, adding up to $1B for molecular glue partnership”

BioSpace’s Biopharma Job Market Report reveals early signs of recovery for 2026. A rise in job postings, a surge in contract roles and strong M&A and IPO activity point to future hiring growth and shifts in hiring strategy.

Original title: “Report: Biopharma Job Market Report Q1 2026”